CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
ABT-199drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01994837
NCT01994837Phase 2Completed
CompareCT.gov

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

AbbVie·interventional·Posted Nov 26, 2013·Updated Jun 6, 2018

In Brief

A Phase 2 clinical trial evaluating ABT-199 for Acute Myelogenous Leukemia and 2 related conditions. Completed, enrolled 32 participants.

Detailed Summary

This was a Phase 2, open-label, multicenter study evaluating the preliminary efficacy and safety of venetoclax (ABT-199) administered orally in participants with acute myelogenous leukemia (AML).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, AML, Acute Myeloid Leukemia
Countries--
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 26, 2013
Enrollment StartNov 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.6 years ago

Interventions

ABT-199drug

Tablet